Biofeedback to treat anxiety in young people at clinical high risk for developing psychosis

Early Intervention in Psychiatry

Volumn 12, Issue 4, 2018, Pages 694-701

  McAusland, Laina ^a   Addington, Jean ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

anxiety; biofeedback; clinical high risk; heart rate variability; psychosis

Indexed keywords

ADOLESCENT; ADULT; ANXIETY; ARTICLE; BIOFEEDBACK; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISTRESS SYNDROME; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART RATE VARIABILITY; HIGH RISK POPULATION; HUMAN; INTERVENTION STUDY; MALE; MOOD DISORDER; OPEN STUDY; PRETEST POSTTEST DESIGN; PRIORITY JOURNAL; PSYCHOSIS; SELF REPORT; STRESS; COMPLICATION; HEART RATE; PHYSIOLOGY; PILOT STUDY; PRODROMAL SYMPTOM; THERAPY; YOUNG ADULT;

ADOLESCENT; ANXIETY; BIOFEEDBACK, PSYCHOLOGY; FEMALE; HEART RATE; HUMANS; MALE; PILOT PROJECTS; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; SELF REPORT; YOUNG ADULT;

EID: 84983775868     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/eip.12368     Document Type: Article

References (53)

1. Braga RJ, Reynolds GP, Siris SG. Anxiety comorbidity in schizophrenia. Psychiatry Res 2013; 210 (1): 1–7.
2. Pallanti S, Cantisani A, Grassi G. Anxiety as a core aspect of schizophrenia. Curr Psychiatry Rep 2013; 15 (5): 354.
3. Achim AM, Maziade M, Raymond E, Olivier D, Mérette C, Roy MA. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 2011; 37 (4): 811–21.
4. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res 2009; 110 (1–3): 1–23.
5. Meyer SE, Bearden CE, Lux SR et al. The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J Child Adolesc Psychopharmacol 2005; 15 (3): 434–51.
6. Kline E, Thompson E, Bussell K, Pitts SC, Reeves G, Schiffman J. Psychosis-like experiences and distress among adolescents using mental health services. Schizophr Res 2014; 152 (2–3): 498–502.
7. Stowkowy J, Colijn MA, Addington J. Pathways to care for those at clinical high risk of developing psychosis. Early Interv Psychiatry 2013; 7 (1): 80–3.
8. Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull 2014; 40 (1): 120–31.
9. McAusland L, Buchy L, Cadenhead KS et al. Anxiety in youth at clinical high risk for psychosis. Early Interv Psychiatry 2015. doi:10.1111/eip.12274.
10. Devylder JE, Ben-David S, Schobel SA, Kimhy D, Malaspina D, Corcoran CM. Temporal association of stress sensitivity and symptoms in individuals at clinical high risk for psychosis. Psychol Med 2013; 43 (2): 259–68.
11. Creswell C, Waite P, Cooper PJ. Assessment and management of anxiety disorders in children and adolescents. Arch Dis Child 2014; 99: 674–8.
12. Wheat AL, Larkin KT. Biofeedback of heart rate variability and related physiology: a critical review. Appl Psychophysiol Biofeedback 2010; 35 (3): 229–42.
13. Dias BG, Banerjee SB, Goodman JV, Ressler KJ. Towards new approaches to disorders of fear and anxiety. Curr Opin Neurobiol 2013; 23 (3): 346–52.
14. Ravindran AV, da Silva TL. Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: a systematic review. J Affect Disord 2013; 150 (3): 707–19.
15. Bourne EJ. The Anxiety & Phobia Workbook. Oakland, CA: New Harbinger Publications, Inc, 2010.
16. Welfare-Wilson A, Newman R. Cognitive behavioural therapy for psychosis and anxiety. Br J Nurs 2013; 22 (18): 1061–5.
17. Braga RJ, Petrides G, Figueira I. Anxiety disorders in schizophrenia. Compr Psychiatry 2004; 45 (6): 460–8.
18. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 2011; 125 (1): 54–61.
19. McGorry PD, Nelson B, Phillips LJ et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry 2013; 74 (4): 349–56.
20. Morrison AP, French P, Stewart SL et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 2012; 344: e2233.
21. Morrison AP, French P, Walford L et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004; 185: 291–7.
22. van der Gaag M, Nieman DH, Rietdijk J et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull 2012; 38 (6): 1180–8.
23. McGlashan TH, Zipursky RB, Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163 (5): 790–9.
24. McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59 (10): 921–8.
25. Ruhrmann S, Bechdolf A, Kühn KU et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 2007; 51: s88–95.
26. Amminger GP, Schäfer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67 (2): 146–54.
27. Martini FH, Bartholomew EF. Essentials of Anatomy & Physiology, 4th edn. San Francisco, CA/London: Pearson/Benjamin Cummings, 2007.
28. Thayer JF, Ahs F, Fredrikson M, Sollers JJ, Wager TD. A meta-analysis of heart rate variability and neuroimaging studies: implications for heart rate variability as a marker of stress and health. Neurosci Biobehav Rev 2012; 36 (2): 747–56.
29. Task Force of the European Society of Cardiology, & The North American Society of Pacing Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation 1996; 93: 1043–65.
30. Bär KJ. Cardiac autonomic dysfunction in patients with schizophrenia and their healthy relatives - a small review. Front Neurol 2015; 6: 139.
31. Clamor A, Hartmann MM, Köther U, Otte C, Moritz S, Lincoln TM. Altered autonomic arousal in psychosis: an analysis of vulnerability and specificity. Schizophr Res 2014; 154 (1–3): 73–8.
32. Montaquila JM, Trachik BJ, Bedwell JS. Heart rate variability and vagal tone in schizophrenia: a review. J Psychiatr Res 2015; 69: 57–66.
33. Valkonen-Korhonen M, Tarvainen MP, Ranta-Aho P et al. Heart rate variability in acute psychosis. Psychophysiology 2003; 40 (5): 716–26.
34. Alvares GA, Quintana DS, Hickie IB, Guastella AJ. Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis. J Psychiatry Neurosci 2015; 40 (6): 140217.
35. Prinsloo GE, Derman WE, Lambert MI, Laurie Rauch HG. The effect of a single session of short duration biofeedback-induced deep breathing on measures of heart rate variability during laboratory-induced cognitive stress: a pilot study. Appl Psychophysiol Biofeedback 2013; 38 (2): 81–90.
36. McGlashan T, Walsh BC, Woods SW. The Psychosis Risk Syndrome: Handbook for Diagnosis and Follow-up. New York: Oxford University Press, 2010.
37. Addington J, Stowkowy J, Cadenhead KS et al. Early traumatic experiences in those at clinical high risk for psychosis. Early Interv Psychiatry 2013; 7 (3): 300–5.
38. Zung WW. A rating instrument for anxiety disorders. Psychosomatics 1971; 12 (6): 371–9.
39. Kessler RC, Andrews G, Colpe LJ et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med 2002; 32 (6): 959–76.
40. First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington: American Psychiatric Press, Inc, 1996.
41. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther 1998; 36 (4): 455–70.
42. Cornblatt BA, Auther AM, Niendam T et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull 2007; 33 (3): 688–702.
43. Kudo N, Shinohara H, Kodama H. Heart rate variability biofeedback intervention for reduction of psychological stress during the early postpartum period. Appl Psychophysiol Biofeedback 2014; 39 (3–4): 203–11.
44. Beckham AJ, Greene TB, Meltzer-Brody S. A pilot study of heart rate variability biofeedback therapy in the treatment of perinatal depression on a specialized perinatal psychiatry inpatient unit. Arch Womens Ment Health 2013; 16 (1): 59–65.
45. Tan G, Dao TK, Farmer L, Sutherland RJ, Gevirtz R. Heart rate variability (HRV) and posttraumatic stress disorder (PTSD): a pilot study. Appl Psychophysiol Biofeedback 2011; 36 (1): 27–35.
46. Zucker TL, Samuelson KW, Muench F, Greenberg MA, Gevirtz RN. The effects of respiratory sinus arrhythmia biofeedback on heart rate variability and posttraumatic stress disorder symptoms: a pilot study. Appl Psychophysiol Biofeedback 2009; 34 (2): 135–43.
47. Siepmann M, Aykac V, Unterdörfer J, Petrowski K, Mueck-Weymann M. A pilot study on the effects of heart rate variability biofeedback in patients with depression and in healthy subjects. Appl Psychophysiol Biofeedback 2008; 33 (4): 195–201.
48. Karavidas MK, Lehrer PM, Vaschillo E et al. Preliminary results of an open label study of heart rate variability biofeedback for the treatment of major depression. Appl Psychophysiol Biofeedback 2007; 32 (1): 19–30.
49. Reiner R. Integrating a portable biofeedback device into clinical practice for patients with anxiety disorders: results of a pilot study. Appl Psychophysiol Biofeedback 2008; 33 (1): 55–61.
50. Wehry AM, Beesdo-Baum K, Hennelly MM, Connolly SD, Strawn JR. Assessment and treatment of anxiety disorders in children and adolescents. Curr Psychiatry Rep 2015; 17 (7): 52.
51. Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 2015; 30 (4): 183–92.
52. Mayo-Wilson E, Dias S, Mavranezouli I et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry 2014; 1 (5): 368–76.
53. van der Zwan JE, de Vente W, Huizink AC, Bögels SM, de Bruin EI. Physical activity, mindfulness meditation, or heart rate variability biofeedback for stress reduction: a randomized controlled trial. Appl Psychophysiol Biofeedback 2015; 40 (4): 257–68.